IMC Immuron

Immuron CEO, Steven Lydeamore to host an investor webinar

Immuron CEO, Steven Lydeamore to host an investor webinar

MELBOURNE, Australia, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, invites investors to join a live webcast hosted by Steven Lydeamore, CEO of Immuron Limited.

Tuesday, 28 February 2023 at 11:00am Australian Eastern Standard Time (AEDT).



To register in advance for this webinar, please follow this link:







After registering, you will receive a confirmation email containing information about joining the webinar.

This release has been authorised by the directors of Immuron Limited.

 COMPANY CONTACT:

 Steven Lydeamore

 Chief Executive Officer

 Ph: +61 (0)3 9824 5254

 

About Immuron

Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases. Immuron has a novel and safe technology platform with one commercial asset generating revenue. In Australia, Travelan® is a listed medicine on the Australian Register of Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Travellers’ Diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan® is a licenced natural health product (NPN 80046016) and is indicated to reduce the risk of Travellers’ Diarrhea. In the U.S., Travelan® is sold as a dietary supplement for digestive tract protection in accordance with section 403 (r)(6) of the Federal Drug Administration (FDA).

For more information visit:



EN
15/02/2023

Underlying

IMCImmuron

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Immuron

 PRESS RELEASE
Free
IMC IMMURON

Immuron Q1 FY26 YoY growth

Immuron Q1 FY26 YoY growth Sales Highlights (unaudited): Global•Q1 sales AUD$2.0 million up 34% on prior comparative period (pcp)   Australia•Q1 sales AUD$1.6 million up 52% on pcp   Canada•Q1 sales AUD$0.0 million down 92% on pcp   USA•Q1 sales AUD$0.4 million up 44% on pcp MELBOURNE, Australia, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce continued sales growth (unaudited) of Travelan®, an over-the-counter immune supplement that targets pathogenic bacteria and th...

October 13, 2025 1 EN
 PRESS RELEASE
Free
IMC IMMURON

Immuron Submits IMM-529 IND to FDA

Immuron Submits IMM-529 IND to FDA Key Points Immuron submits Investigational new drug (IND) application to FDA for clinical development of IMM-529 as product to specifically prevent or treat Clostridioides difficile infection (CDI)Previous clinical trial data on IMM-529 provides support for continued development of IMM-529 MELBOURNE, Australia, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), is pleased to announce that it has submitted an Investigational New Drug (IND) application to the United States Food and Drug Administration (FDA) for clinical developm...

October 8, 2025 1 EN
 PRESS RELEASE
Free
IMC IMMURON

Immuron Letter to Shareholders – Projects Update

Immuron Letter to Shareholders – Projects Update Highlights: US Tariffs: Immuron does not anticipate any material impact from the recently announced US tariffs on pharmaceutical productsTravelan® Clinical Study: Topline results from the Travelan® clinical study conducted by Uniformed Services University are anticipated in October 2025 IMM-529 Regulatory Milestone: Immuron plans to submit an Investigational New Drug (IND) application to the U.S. FDA for IMM-529 (Clostridiodes difficile infection) in mid-October 2025ProIBS® Commercial Launch: The Australian Launch of ProIBS® is on track for ...

October 2, 2025 1 EN
 PRESS RELEASE
Free
IMC IMMURON

Immuron partners with InvestorHub

Immuron partners with InvestorHub MELBOURNE, Australia, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) advises it has entered into a partnership with InvestorHub, a direct-to-investor engagement software company that provides public companies the digital capabilities to build direct and interactive relationships with investors. In line with the Company’s commitments to better inform and engage with investors and stakeholders, we have launched our interactive investor hub - bringing content and communication into a single integrated platform. The Company will...

August 27, 2025 1 EN
 PRESS RELEASE
Free
IMC IMMURON

Immuron - FY25 global sales exceed projection, up 49% on prior year

Immuron - FY25 global sales exceed projection, up 49% on prior year Sales Highlights (unaudited): Global Annual sales AUD$7.3 million up 49% on prior yearJune 2025 Quarter AUD$2.0 million up 55% on prior year Australia Annual sales AUD$5.2 million up 40% on prior yearJune 2025 Quarter AUD$1.5 million up 58% on prior year North America Annual sales AUD$2.0 million up 76% on prior yearJune 2025 Quarter AUD$0.5 million up 49% on prior year MELBOURNE, Australia, July 17, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmace...

July 17, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch